Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy

Hemoglobin

Volumn 30, Issue 1, 2006, Pages 105-112

  Cermák, Jaroslav ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Chelation; Deferiprone (L1); Erythropoietin (EPO); Ferritin; Iron overload; Myelodysplastic syndrome (MDS)

Indexed keywords

DEFERIPRONE; RECOMBINANT ERYTHROPOIETIN;

BLOOD TRANSFUSION; BONE MARROW; CHELATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE; GASTROINTESTINAL SYMPTOM; HUMAN; IRON BALANCE; IRON OVERLOAD; NAUSEA AND VOMITING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANEMIA, REFRACTORY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; IRON CHELATING AGENTS; MYELODYSPLASTIC SYNDROMES; PYRIDONES;

EID: 33645088422     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260500455375     Document Type: Conference Paper

References (18)

1. Bowen DT, Hellström-Lindberg E. Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy? Leuk Res 2001; 25(1):19-21.
2. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005; 252(6):536-538.
3. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Oberg G, Porwit-MacDonald A, Radlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F, Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120(6):1037-1046.
4. Eschbach JW. Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol 2005; 18(2):347-361.
5. Kontoghiorhes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and applications prospects. Curr Med Chem 2004; 11(11):2161-2183.
6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51(2):189-199.
7. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization(WHO) International Working Group Report of an international working group to standardize response criteria for myelodysplastic syndrome. Blood 2000; 96(12):3671-3674.
8. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17(12):3835-3849.
9. Raza A, Gregory SA, Preisler HD. The myelodysplastic syndrome in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996; 20(11-12):881-890.
10. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79(8):1987-1994.
11. Vreugdenhil G, Kontoghiorghes HG, van Eijk HG, Swaak AJG. Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxipyrid-4-one. Clin Exp Rheumatol 1991; 9(1):35-40.
12. Ganz T. Hepcidin - a regulator of intestinal kon absorption and iron recycling by macrophages. Best Prac Res Clin Haematol 2005; 18(2):171-182.
13. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, Locatelli F, Marchetti M, Morra E, Rebulla P, Visani G, Tura S, Italian Society of Hematology. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87(12):1286-1306.
14. Cermák J, Michalová K, Brezinová J, Zemanová Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary MDS. Leuk Res 2003; 27(3):221-229.
15. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990; 76(2):295-300.
16. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J, UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120(2):187-200.
17. Asano H, Ohashi H, Ichihara M, Kinoshita T, Murate T, Kobayashi M, Saito H, Hotta T. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 1994; 84(2):588-594.
18. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F. The safety and effectiveness of deferiprone in a large-scale, 3-year studyin Italian patients. Br J Haematol 2002; 118(2):330-336.